Acta Neuropharmacologica››2013,Vol. 3››Issue (5): 2-12.
GUO Lin, ZHEN Xue-chu
Online:2013-10-26Published:2014-06-27Contact:镇学初，男，教授，博士生导师；研究方向：神经精神药理；Tel：+86-0512-65880369，E-mail：zhenxuechu@suda.edu.cnAbout author:郭琳，男，博士；研究方向：神经药理；Tel：+86-0512-65880369，E-mail：guolin0724@163.comGUO Lin, ZHEN Xue-chu.An Update on Antipsychotic Drugs: New Targets and New Mechanisms[J]. Acta Neuropharmacologica, 2013, 3(5): 2-12.
| [1] John McGrath, Sukanta Saha, David Chant, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality[J]. Epidemiol Rev, 2008, 30: 67-76. [2] Erick L Messias, Chen Chuan-yu, William W Eaton. Epidemiology of schizophrenia: review of findings and myths[J]. Psychiatr Clin North Am, 2007, 30(3): 323-338. [3] Evelyn J Bromet, Shmuel Fennig. Epidemiology and natural history of schizophrenia[J]. Biol Psychiatry, 1999, 46(7): 871-881. [4] Pavo Filakovic, Anamarija Petek Eric. Pharmacotherapy of suicidal behaviour in major depression, schizophrenia and bipolar disorder[J]. Coll Antropol, 2013, 37(3): 1039-1044. [5] Murat Pakyurek, Rodney Yarnal, Cameron Carter. Treatment of psychosis in children and adolescents: a review[J]. Adolesc Med State Art Rev, 2013, 24(2): 420-432, ix. [6] David A Lewis, Jeffrey A Lieberman. Catching up on schizophrenia: natural history and neurobiology[J]. Neuron, 2000, 28(2): 325-334. [7] David St Clair, Xu Ming-qing, Wang Peng, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961[J]. JAMA, 2005, 294(5): 557-562. [8] Ann B Goodman. Three independent lines of evidence suggest retinoids as causal to schizophrenia[J]. Proc Natl Acad Sci USA, 1998, 95(13): 7240-7244. [9] Ezra S Susser, Shang P Lin. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945[J]. Arch Gen Psychiatry, 1992, 49(12): 983-988. [10] Manti Srisurapanont, Robert Ali, John Marsden, et al. Psychotic symptoms in methamphetamine psychotic in-patients[J]. Int J Neuropsychopharmacol, 2003, 6(4): 347-352. [11] Tune L E, Wong D F, Pearlson G, et al. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone[J]. Psychiatry Res, 1993, 49(3): 219-237. [12] Gerhard Gross, Karla Drescher. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions[J]. Handb Exp Pharmacol, 2012, 213: 167-210. [13] Ye Na, Wu Qian-qian, Zhu Li-yuan, et al. Further SAR study on 11-O-substituted aporphine analogues: identification of highly potent dopamine D3 receptor ligands[J]. Bioorg Med Chem, 2011, 19(6): 1999-2008. [14] Truffinet Philippe, Carol A Tamminga, Louis F Fabre, et al. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia[J]. Am J Psychiatry, 1999, 156(3): 419-425. [15] Tsuyoshi Hirose, Tetsuro Kikuchi. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist[J]. J Med Invest, 2005, 52 Suppl: 284-290. [16] Adrian Newman-Tancredi, Mark S Kleven. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties[J]. Psychopharmacology (Berl), 2011, 216(4): 451-473. [17] Philip Seeman, Johannes Schwarz, Chen Jiang-fan, et al. Psychosis pathways converge via D2high dopamine receptors[J]. Synapse, 2006, 60(4): 319-346. [18] Yoshihiro Tadori, Rpbert A Forbes, Robert D McQuade, et al. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors[J]. Eur J Pharmacol, 2009, 607(1-3): 35-40. [19] Ross Zimnisky, Gloria Chang, Istvan Gyertyan, et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse[J]. Psychopharmacology (Berl), 2013, 226(1): 91-100. [20] Tanja Veselinovic, Michael Paulzen, Garhard Grunder. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression[J]. Expert Rev Neurother, 2013, 13(11): 1141-1159. [21] Minda R Lynch. Schizophrenia and the D1 receptor: focus on negative symptoms[J]. Prog Neuropsychopharmacol Biol Psychiatry, 1992, 16(6): 797-832. [22] Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory[J]. Science, 1991, 251(4996): 947-950. [23] Jun Kosaka, Hidehiko Takahashi, Hiroshi Ito, et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia[J]. Life Sci, 2010, 86(21-22): 814-818. [24] Tomokazu Nakako, Takeshi Murai, Masaru Ikejiri, et al. Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets[J]. Behav Brain Res, 2013, 249: 109-115. [25] Shikha Snigdha, Nagi Idris, Ben Grayson, et al. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism[J]. Psychopharmacology (Berl), 2011, 214(4): 843-853. [26] Patricia S Goldman-Rakic, Stacy A Castner, Torgny H Svensson, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction[J]. Psychopharmacology (Berl), 2004, 174(1): 3-16. [27] Davis K L, Kahn R S, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization[J]. Am J Psychiatry, 1991, 148(11): 1474-1486. [28] Sridhar Natesan, Greg E Reckless, Karen B Barlow, et al. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist[J]. Psychopharmacology (Berl), 2008, 199(2): 275-289. [29] Mo Jiao, Guo Yang, Yang Yu-she, et al. Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications[J]. Curr Med Chem, 2007, 14(28): 2996-3002. [30] Guo Yang, Zhang Hai, Chen Xue-tao, et al. Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand[J]. Schizophr Res, 2009, 115(1): 41-49. [31] Heinz E Lehmann, Thomas A Ban. The history of the psychopharmacology of schizophrenia[J]. Can J Psychiatry, 1997, 42(2): 152-162. [32] Meltzer H Y, Massey B W. The role of serotonin receptors in the action of atypical antipsychotic drugs[J]. Curr Opin Pharmacol, 2011, 11(1): 59-67. [33] Herbert Y Meltzer, Li Zhu, Yasuhiro Kaneda, et al. Serotonin receptors: their key role in drugs to treat schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27(7): 1159-1172. [34] Snigdha S, Horiguchi M, Huang M, et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist[J]. J Pharmacol Exp Ther, 2010, 332(2): 622-631. [35] Judith A Siuciak, Douglas S Chapin, Sheryl A McCarthy, et al. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity[J]. Neuropharmacology, 2007, 52(2): 279-290. [36] Michael Maes, Herbert Y Meltzer. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers[J]. Psychiatry Res, 1996, 64(3): 147-159. [37] Vincenzo Di Matteo, Giuseppe Di Giovanni, Michele Di Mascio, et al. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors[J]. Brain Res, 2000, 865(1): 85-90. [38] Laia Llado-Pelfort, Noemi Santana, Valentina Ghisi, et al. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons[J]. Cereb Cortex, 2012, 22(7): 1487-1497. [39] M Victoria Puig, Akiya Watakabe, Mika Ushimaru, et al. Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors[J]. J Neurosci, 2010, 30(6): 2211-2222. [40] Farhat Batool, Darakhshan J Haleem. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats[J]. Pak J Pharm Sci, 2008, 21(4): 411-420. [41] Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives[J]. Curr Opin Investig Drugs, 2010, 11(7): 802-812. [42] Marilyn A Davies, Douglas J Sheffler, Bryan L Roth. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology[J]. CNS Drug Rev, 2004, 10(4): 317-336. [43] Jorn Arnt, Benny Bang-Andersen, Ben Grayson, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats[J]. Int J Neuropsychopharmacol, 2010, 13(8): 1021-1033. [44] Zoltan Doleviczenyi, E Sylvester Vizi, Istvan Gacsalyi, et al. 5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism[J]. Neurochem Res, 2008, 33(11): 2364-2372. [45] Katarzyna Fijal, Pitor Popik, Agnieszka Nikiforuk. Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats[J]. Psychopharmacology (Berl), 2014, 231(1): 269-281. [46] Julie Meffre, Severine Chaumont-Dubel, Clotilde Mannoury la Cour, et al. 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia[J]. EMBO Mol Med, 2012, 4(10): 1043-1056. [47] Agnieszka Nikiforuk, Tomasz Kos, Katarzyna Fijal, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats[J]. PLoS One, 2013, 8(6): e66695. [48] Agnieszka Nikiforuk, Piotr Popik. Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors[J]. Behav Brain Res, 2013, 248: 136-140. [49] Ann M Mortimer. Novel antipsychotics in schizophrenia[J]. Expert Opin Investig Drugs, 2004, 13(4): 315-329. [50] Amy R Mohn, Raul R Gainetdinov, Marc G Caron, et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia[J]. Cell, 1999, 98(4): 427-436. [51] Joseph T Coyle, Alo Basu, Michael Benneyworth, et al. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications[J]. Handb Exp Pharmacol, 2012, 213: 267-295. [52] Justine M Kent, Jeremy D Coplan, llise Lombardo, et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652[J]. Psychopharmacology(Berl), 2002, 164(4): 341-348. [53] Danuel C Javitt. Glutamatergic theories of schizophrenia[J]. Isr J Psychiatry Relat Sci, 2010, 47(1): 4-16. [54] Daniel C Javitt. Glycine transport inhibitors in the treatment of schizophrenia[J]. Handb Exp Pharmacol, 2012, 213: 367-399. [55] Toshiharu Shimazaki, Ayaka Kaku, Shigeyuki Chaki. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats[J]. Psychopharmacology (Berl), 2010, 209(3): 263-270. [56] Kenji Hashimoto, Yuko Fujita, Tamaki Ishima, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine[J]. Eur Neuropsychopharmacol, 2008, 18(6): 414-421. [57] Hsien-yuan Lane, Lin Ching-hua, Yu-jhen Huang, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia[J]. Int J Neuropsychopharmacol, 2010, 13(4): 451-460. [58] Liem-Moolenaar M, Zoethout R W, de Boer P, et al. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects[J]. J Psychopharmacol, 2010, 24(11): 1681-1687. [59] Kenji Hashimoto, Berend Malchow, Peter Falkai, et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders[J]. Eur Arch Psychiatry Clin Neurosci, 2013, 263(5): 367-377. [60] Chiara Procaccini, Milica Maksimovic, Teemu Aitta-Aho, et al. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740[J]. Neuroscience, 2013, 250: 189-200. [61] P Jeffrey Conn, Carrie K Jones. Promise of mGluR2/3 activators in psychiatry[J]. Neuropsychopharmacology, 2009, 34(1): 248-249. [62] Trabanco A A, Cid J M, Lavreysen H, et al. Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2[J]. Curr Med Chem, 2011, 18(1): 47-68. [63] Meiis Inan, Timothy J Petros, Stewart A Anderson. Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia[J]. Neurobiol Dis, 2013, 53: 36-48. [64] Alessandro Guidotti, James Auta, John M Davis, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon[J]. Psychopharmacology (Berl), 2005, 180(2): 191-205. [65] Peter M Haddad, Amlan Das, Muhammad Ashfaq, et al. A review of valproate in psychiatric practice[J]. Expert Opin Drug Metab Toxicol, 2009, 5(5): 539-551. [66] Sawako Arai, Kazuhiro Takuma, Hiroyuki Mizoguchi, et al. GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice[J]. Eur J Pharmacol, 2009, 602(1): 101-104. [67] Sawako Arai, Kazuhiro Takuma, Hiroyuki Mizoguchi, et al. Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen[J]. Neuropsychopharmacology, 2008, 33(13): 3164-3175. [68] Gandal M J, Sisti J, Klook K, et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction[J]. Transl Psychiatry, 2012, 2: e142. [69] Uwe Rudolph, Hanns Mohler. GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 483-507. [70] Noemi Santana, Guadalupe Mengod, Francesc Artigas. Expression of alpha(1)-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT(2A) receptors[J]. Int J Neuropsychopharmacol, 2013, 16(5): 1139-1151. [71] Olivia Franberg, Monica M Marcus, Torgny H Svensson. Involvement of 5-HT2A receptor and alpha2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow[J]. Synapse, 2012, 66(7): 650-660. [72] Alexander G E, Crutcher M D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing[J]. Trends Neurosci, 1990, 13(7): 266-271. [73] Jan Kehler, Jacob Nielsen. PDE10A inhibitors: novel therapeutic drugs for schizophrenia[J]. Curr Pharm Des, 2011, 17(2): 137-150. [74] Weber M, Breier M, Ko D, et al. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine[J]. Psychopharmacology (Berl), 2009, 203(4): 723-735. [75] Schmidt C J, Chapin D S, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia[J]. J Pharmacol Exp Ther, 2008, 325(2): 681-690. [76] Tamminga C A, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis[J]. Curr Drug Targets CNS Neurol Disord, 2002, 1(2): 141-147. [77] Francois Gastambide, Marie Caroline Cotel, Gary Gilmour, et al. Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator[J]. Neuropsychopharmacology, 2012, 37(4): 1057-1066. |
| [1] | ZHANG Shuai，AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20. |
| [2] | HU Wei-wei, CHEN Zhong.Dissection of the Role of Cell Type Specific Histamine Receptors in Central Nervous System Disorders[J]. Acta Neuropharmacologica, 2018, 8(5): 88-89. |
| [3] | ZHANG Xiang-yang.Neurocognitive Impairment in Schizophrenia: Clinical Correlates and Pathophysiological Mechanisms[J]. Acta Neuropharmacologica, 2018, 8(5): 89-90. |
| [4] | SUN Yan-yun，WANG Meng-wei，JIN Xin-chu.Chronic Nicotine Treatment Alleviates Schizophrenia-Induced Memory Deficit through Regulating Pdlim5 and CRTC1 in Mice[J]. Acta Neuropharmacologica, 2018, 8(4): 6-7. |
| [5] | Gill SE1,5#，Halene T1,6#，Rajarajan P2，Chandrasekaran S2，Kassim B1，Fullard JF1,5，Loh YHE8，Bannon MJ7，.3D Genome Mapping in Dopaminergic Neurons from Adult Human Midbrain[J]. Acta Neuropharmacologica, 2018, 8(4): 31-32. |
| [6] | WANG Xiao-na, ZHANG Xin-yu, SUN Yan-yun, JIN Xin-chun.D1 Receptor-Mediated Endogenous tPA Upregulation Contributes to Acute Blood Brain Barrier Damage[J]. Acta Neuropharmacologica, 2018, 8(4): 58-59. |
| [7] | BAI Hui, ZHANG Ming, ZHANG Wei.Progress in Glutamate Receptor Auxiliary Subunit[J]. Acta Neuropharmacologica, 2015, 5(2): 24-29. |
| [8] | LING Peng，LI Yue-yue，QIAN Heng，LIAN Xiao-yuan.Regulation of Excitatory Amino Acid Neurotransmitter by Astrocytes and Its Impact to Epilepsy[J]. Acta Neuropharmacologica, 2015, 5(2): 46-53. |
| [9] | LI Jing, SUN Jian-dong, YUAN Yu-he, CHEN Nai-hong.Progress in Studies of Glutamatergic Neurotransmission in the Pathogenesis of Depression[J]. Acta Neuropharmacologica, 2014, 4(1): 20-24. |
| [10] | ZHEN Li-qing.GABAA Receptor Drugs and Neuronal Plasticity[J]. Acta Neuropharmacologica, 2012, 2(6): 40-48. |
| [11] | DONG Dong，WANG Rui.Progress of receptors, cytokine and signal pathways about depression[J]. Acta Neuropharmacologica, 2012, 2(5): 24-30. |
| [12] | GAO Hai-xia, QIAO Xiao-wen, DUN Jie-ning, DONG Ming-gang，XU Zhi-wei,ZHANG Hai-lin.Transient Receptor Potential Melastatin 7 Involved in the Proliferation Induced by Platelet Derived Growth Factor and 5-HT in Pulmonary Artery Smooth Muscle Cells of Rates[J]. Acta Neuropharmacologica, 2012, 2(3): 15-21. |
| [13] | ZHAO Nan，ZHANG You-zhi，YANG Ming，WANG Yi-wen，ZHAO Yi-min，GONG Ze-hui，LI Yun-feng.The Antidepressant Effect of the Total Flavonoids Extracted fromCottonseed and its Regulation on Hippocampal Monoamines[J]. Acta Neuropharmacologica, 2011, 1(4): 6-11. |
| [14] | LI Dong-wei, DOU De-qiang.Research Advances in Using Ginseng to Prevent and Treat Parkinson’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2011, 1(4): 55-64. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
